Navigation Links
deCODE genetics Announces Third Quarter 2007 Financial Results
Date:11/5/2007

de.is info@decode.is info@decode.is

Condensed Consolidated Statements of Operations

For the three months For the nine months

ended September 30, ended September 30,

2007 2006 2007 2006

in thousands, except per share amounts (unaudited)

Revenue $10,892 $8,566 $27,060 $29,059

Operating expenses

Cost of revenue 11,976 11,357 32,050 31,666

Research and

development 14,069 14,178 41,273 42,902

Selling, general and

administrative 7,070 6,938 19,395 16,597

Total operating

expense 33,115 32,473 92,718 91,165

Operating loss (22,223) (23,907) (65,658) (62,106)

Interest income 1,646 1,834 5,155 4,882

Interest expense. (4,019) (1,728) (11,488) (5,135)

Other non-operating

income and (expense),

net 348 169 8,890 111

Net loss $(24,248) $(23,632) $(63,101) $(62,248)

Basic and diluted net

loss per share: $(0.40) $(0.40) $(1.03) $(1.11)

Shares used in computing

basic and diluted net

loss per share 61,033 59,616 60,996 56,333

Condensed Consolidated Balance Sheet Data

At September 30, At December 31,

2007 2006

in thous
'/>"/>

SOURCE deCODE genetics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
4. Response Genetics Reports Second Quarter 2007 Financial Results
5. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 2BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 3BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines 4Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6
Breaking Biology News(10 mins):Self-destructing bacteria improve renewable biofuel production 2Self-destructing bacteria improve renewable biofuel production 3IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2Hybrid Concierge Medical Practice Provides More Value Options to Growing Number of Physicians Nationwide 51040 1Hybrid Concierge Medical Practice Provides More Value Options to Growing Number of Physicians Nationwide 51040 2Hybrid Concierge Medical Practice Provides More Value Options to Growing Number of Physicians Nationwide 51040 3The Max Cure Foundation Announces Its First Charity Benefit 3A The Roar for a Cure Carnival to Be Held on Saturday August 22 2009 51038 1The Max Cure Foundation Announces Its First Charity Benefit 3A The Roar for a Cure Carnival to Be Held on Saturday August 22 2009 51038 2The Max Cure Foundation Announces Its First Charity Benefit 3A The Roar for a Cure Carnival to Be Held on Saturday August 22 2009 51038 3The Max Cure Foundation Announces Its First Charity Benefit 3A The Roar for a Cure Carnival to Be Held on Saturday August 22 2009 51038 4The Max Cure Foundation Announces Its First Charity Benefit 3A The Roar for a Cure Carnival to Be Held on Saturday August 22 2009 51038 5Insulet Establishes Eco Friendly Disposal Program for the OmniPod 28R 29 Insulin Management System 51036 1Insulet Establishes Eco Friendly Disposal Program for the OmniPod 28R 29 Insulin Management System 51036 2